Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia

Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia

Bibliographic Details
Main Authors:	Julio Delgado, Miguel Caballero-Baños, Valentín Ortiz-Maldonado, Maria Castellà, Laura Magnano, Manel Juan, Álvaro Urbano-Ispizua
Format:	Article
Language:	English
Published:	Wiley 2019-04-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000174

Similar Items

Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation
by: Valentín Ortiz-Maldonado, et al.
Published: (2022-01-01)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
by: Bartosz Puła, et al.
Published: (2019-11-01)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
by: Keisuke Kidoguchi, et al.
Published: (2021-02-01)

Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
by: Yixin Zou, et al.
Published: (2018-11-01)

Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
by: Yanyan Liu, et al.
Published: (2022-08-01)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
by: Benjamin Arthurs, MD, et al.
Published: (2017-01-01)

Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing
by: Nuria Martinez-Cibrian, et al.
Published: (2022-09-01)

A decade of CD4+ chimeric antigen receptor T-cell evolution in two chronic lymphocytic leukemia patients: were chronic lymphocytic leukemia cells present?
by: Dimitrios Bouzianas, et al.
Published: (2023-10-01)

449 Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy
by: Julie Rytlewski, et al.
Published: (2021-11-01)

CD19 Chimeric Antigen Receptor-Exosome Targets CD19 Positive B-lineage Acute Lymphocytic Leukemia and Induces Cytotoxicity
by: Shabirul Haque, et al.
Published: (2021-03-01)

Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia
by: Ayşe Kaya, et al.
Published: (2024-03-01)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
by: Paul J. Hampel, et al.
Published: (2022-09-01)

Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia
by: Rohan Beresford, et al.
Published: (2019-06-01)

Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report
by: Anna-Eve Turcotte, et al.
Published: (2023-01-01)

FRAILTY ASSESSMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH THE COMBINATION OF VENETOCLAX AND IBRUTINIB
by: TX Carneiro, et al.
Published: (2023-10-01)

EXPERIENCE WITH IBRUTINIB IN PATIENTS WITH REFRACTORY AND RECURRENT B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
by: T. V. SOROKINA, et al.
Published: (2017-06-01)

COVID-19 IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN USE OF IBRUTINIB: NOT THAT RISKY?
by: M.L.B.F. Dourado, et al.
Published: (2020-11-01)

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy
by: Ayad M. Al‐Katib, et al.
Published: (2020-09-01)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
by: Gina Ma, et al.
Published: (2018-01-01)

P654: IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH COMPLEX KARYOTYPE AND CHRONIC LYMPHOCYTIC LEUKEMIA
by: A. Petrenko, et al.
Published: (2022-06-01)

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
by: Francesca Romana Mauro, et al.
Published: (2021-06-01)

Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment
by: Subir Roy Chowdhury, et al.
Published: (2020-03-01)

Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib
by: Anna Christoforidou, et al.
Published: (2018-05-01)

Progressive multifocal leukoencephalopathy in a patient with relapsed chronic lymphocytic leukemia treated with Ibrutinib
by: Larissa Lane Cardoso Teixeira, et al.
Published: (2022-07-01)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
by: Sara Bravaccini, et al.
Published: (2020-09-01)

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
by: Maria Cristina Puzzolo, et al.
Published: (2021-04-01)

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
by: Tucker DL, et al.
Published: (2015-06-01)

Successful Treatment of Ocular Chronic Lymphocytic Leukemia with Ibrutinib: Case Report and Review of the Literature
by: Ayushi F Chauhan, et al.
Published: (2020-01-01)

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
by: Justin C. Boucher, et al.
Published: (2023-12-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Isacco Ferrarini, et al.
Published: (2022-04-01)

RAPID REDUCTION OF LYMPH NODE ENLARGEMENT IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB
by: JOR Cassiano, et al.
Published: (2023-10-01)

Behçet's disease‐like clinical manifestations of chronic lymphocytic leukemia during good response to ibrutinib
by: Kosuke Obama, et al.
Published: (2023-08-01)

Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia
by: Gülşen İskender, et al.
Published: (2020-08-01)

Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia
by: Josh A. Hammel, MD, et al.
Published: (2017-05-01)

“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”
by: Maurizio Cavallari, et al.
Published: (2017-01-01)

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
by: Cheng Zhang, et al.
Published: (2022-06-01)

Successful Management of Ibrutinib-Induced Thrombocytopenia in a Patient with Chronic Lymphocytic Leukemia: No Interruption, Only Reduction
by: Simge Erdem, et al.
Published: (2024-03-01)

P659: IBRUTINIB IN OVER-EIGHTIES PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTER ITALIAN COHORT
by: G. Reda, et al.
Published: (2022-06-01)

PB1908: NRF2 INHIBITION IN COMBINATION WITH IBRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA– AN IN VITRO STUDY
by: Joana Jorge, et al.
Published: (2023-08-01)

Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinib
by: Baustin M. Welch, et al.
Published: (2023-12-01)